Inhibrx ROCE
Mi az Inhibrx ROCE?
A ROCE az Inhibrx, Inc. - 758.45%
Mi a ROCE meghatározása?
A befektetett tőke megtérülése (ROCE) olyan pénzügyi arány, amely a vállalat jövedelmezőségét és a tőke felhasználásának hatékonyságát méri.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE a Health Care szektor a NASDAQ-on cégekben a Inhibrx -hoz képest
Mit csinál Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
roce -hoz hasonló cégek Inhibrx
- Molecular Data Inc nak ROCE 682.69% van
- 9 Meters Biopharma nak ROCE 684.23% van
- Biosig Technologies Inc nak ROCE 689.29% van
- BioCardia nak ROCE 724.72% van
- Elfato nak ROCE 731.09% van
- ContraFect Corp nak ROCE 754.78% van
- Inhibrx nak ROCE 758.45% van
- Corvus Gold nak ROCE 760.11% van
- Havn Life Sciences Inc nak ROCE 763.04% van
- Sabine Royalty Trust nak ROCE 785.68% van
- Winners nak ROCE 793.33% van
- American Environmental nak ROCE 831.71% van
- Killi nak ROCE 837.33% van